[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"palliative-radiotherapy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:palliative-radiotherapy":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,46,68,94,116],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100642215","lattice-radiotherapy-for-adults-with-large-tumors-100642215",false,"NCT07647679","Lattice Radiotherapy for Adults With Large Tumors","Pilot Study of Lattice Radiotherapy in Adults With Large Tumors","LRT","Inclusion Criteria:\n\n* Histologically or cytologically confirmed malignancy diagnosis\n* Radiographic evidence of large extracranial tumor (≥ 4.5 cm)\n* Patients with primary or metastatic extracranial tumors may be included\n* Planned to undergo palliative radiation treatment\n* Life expectancy of at least 3 months\n* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 3\n* Patient must sign study-specific informed consent\n\nExclusion Criteria:\n\n* Primary lesion with radiosensitive histology (i.e. germ cell tumors, lymphoma, leukemia, and multiple myeloma)\n* Prior radiation treatment that overlaps with any planned site of protocol radiotherapy that would preclude further palliative RT.\n* Receiving concurrent cytotoxic cancer therapy regimens or Vascular Endothelial Growth Factor (VEGF) inhibitor that would overlap with LRT administration. Cytotoxic chemotherapy, targeted therapies, small molecule inhibitors, or sVEGF inhibitors prior to radiation treatment or planned after radiation delivery are allowed at the discretion of the treating radiation oncologist.","ALL","18 Years",{"count":20,"type":21},25,"ESTIMATED","INTERVENTIONAL",[24],"NA","The purpose of this study is to ask whether using a specialized radiation therapy technique called Lattice Radiation Therapy (LRT) can shrink large tumors when given with palliative radiation therapy. The primary questions are:\n\n* if LRT is safe and does not worsen existing side effects or cause new side effects\n* if adding LRT to standard radiation therapy can improve tumor shrinkage. Participants will have one additional radiation treatment (LRT) prior to starting palliative radiation and then their progress will be followed for one year.",[27,28],"Large Tumor","Palliative Radiotherapy",[30,31,32],"palliative radiation therapy","large tumor","lattice radiation therapy (LRT)","NOT_YET_RECRUITING","2026-06-29",{"date":36,"type":37},"2026-07-01","ACTUAL",{"date":39,"type":21},"2026-08-01",{"date":41,"type":21},"2030-08",{"name":43,"class":44},"Duke University","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":45},"100412328","advanced-techniques-for-single-fraction-palliative-radiotherapy-versus-standard-multi-fraction-radiation-100412328","NCT04649125","Advanced Techniques For Single-fraction Palliative Radiotherapy Versus Standard Multi Fraction Radiation","ASPIRE_Multi","Inclusion Criteria:\n\n* Metastatic cancer\n* Recommended for 5-10 fractions palliative radiation\n* Patients with spinal cord compression are eligible for enrolment\n\nExclusion Criteria:\n\n* Unwilling or unable to give informed consent\n* Patients who are recommended for single fraction palliative radiation",{"count":54,"type":21},100,[24],"The aim of the study is to determine if single fraction dose escalated palliative radiotherapy results in a prolonged duration of benefit for patients otherwise suitable for Multifraction (5-10#) palliative radiation. The primary endpointis to determine the percentage of patients who have achieved a substantial benefit from palliative radiotherapy and have not redeveloped symptoms by 12 months post treatment",[28],"RECRUITING","2026-02-04",{"date":61,"type":37},"2026-02-06",{"date":63,"type":37},"2021-05-31",{"date":65,"type":21},"2026-06-30",{"name":67,"class":44},"Royal North Shore Hospital",{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":22,"phases":77,"briefSummary":79,"conditions":80,"keywords":82,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":45},"100575909","phase-2-hybrid-arc-palliative-radiation-therapy-hart-a-single-arm-phase-ii-trial-100575909","NCT06778408","Hybrid Arc Palliative Radiation Therapy (HART): A Single Arm Phase II Trial","HART","Inclusion Criteria:\n\nHistological confirmation of cancer with radiographic (CT, MRI or PET) evidence of metastatic disease\n\nPalliative radiotherapy indicated for bone or soft tissue metastases, or primary targets, located in the thorax, abdomen, or pelvis as part of their standard of care treatment plan\n\nAge ≥ 18 years.\n\nWomen of child-bearing potential and men must agree to use adequate contraception prior to study entry, for the duration of study participation, and for 90 days following completion of therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.\n\nIn lieu of a pregnancy test, participants may sign the Pregnancy Attestation Form, a standard form routinely used in clinical practice at UVMCC.\n\nRecommended methods of birth control are:\n\nThe consistent use of an approved hormonal contraception (birth control pill\u002Fpatches, rings), An intrauterine device (IUD), Contraceptive injection (Depo-Provera), Double barrier methods (Diaphragm with spermicidal gel or condoms with contraceptive foam), Sexual abstinence (no sexual intercourse) or Sterilization.\n\nMen must agree to use a condom and not father a child or donate sperm for the duration of the study and for 90 days after completion of therapy.\n\nA female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:\n\n* Has not undergone a hysterectomy or bilateral oophorectomy; or\n* Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months).\n\nAbility to understand and the willingness to sign a written informed consent.\n\nExclusion Criteria:\n\nPatients receiving any other investigational agents or concurrent cytotoxic chemotherapy\n\nPatients who are pregnant or nursing due to the potential for congenital abnormalities and the potential of this regimen to harm nursing infants.\n\nSerious medical comorbidities, which in the opinion of the radiation oncologist preclude the delivery of RT",{"count":76,"type":21},103,[78],"PHASE2","This is a prospective single-center single-arm Phase II trial of HART for patients with metastatic cancer. The primary objective is to assess the incidence of acute GI toxicity following HART. PRO-CTCAE GI scores observed in the study patients will be compared to historical rates. Secondary outcomes include measuring changes in health-related quality of life, esophageal quality of life, toxicity, dosimetric outcomes, and pain.",[28,81],"Metastatic Cancer (Different Solid Tumour Types)",[83,84],"palliative","radiotherapy","2026-02-02",{"date":87,"type":37},"2026-02-05",{"date":89,"type":37},"2025-04-28",{"date":91,"type":21},"2028-03",{"name":93,"class":44},"University of Vermont Medical Center",{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":4,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":101,"targetDuration":4,"studyType":22,"phases":103,"briefSummary":104,"conditions":105,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":45},"100615383","high-dose-radiotherapy-for-palliation-hi-d-100615383","NCT07291895","High Dose Radiotherapy for Palliation (Hi-D)","A Prospective Single-blinded Randomized Study of High Dose Radiotherapy for Palliation: Hi-D","Inclusion Criteria:\n\n* Subjects must meet all the following criteria to be eligible for participation in this study:\n* Age 18 or older.\n* Able to provide informed consent\n* Patient has histologically confirmed solid tumour malignancy\n* ECOG performance status 0 - 2\n* Life Expectancy \\> 6 months\n* 1-5 target lesions larger than 5cm\n* A history and physical exam, including ECOG performance status, performed within 6 weeks prior to trial enrollment\n* Not suitable for or declined curative-intent treatment\n* Subject has had a CT neck, chest, abdomen and pelvis or PET-CT within 8 weeks prior to enrollment, and with 12 weeks of treatment\n* MRI spine for patients receiving RT to vertebral or paraspinal metastases\n* Patient is judged able to:\n\n  * Maintain a stable position during therapy\n  * Tolerate immobilization device(s) that may be required to deliver radiation safely\n\nExclusion Criteria:\n\n* \\- Hematologic malignancy.\n* Disease limited to intracranial sites\n* Serious medical co-morbidities precluding radiotherapy\n* Bone metastases with no soft tissue component\n* Prior radiation to target lesion that precludes delivery of repeat radiation. All such cases should be discussed with the local and study PIs.\n* Pregnant women",{"count":102,"type":21},20,[24],"The goal of this clinical trial is to evaluate the feasibility of single-blind randomization between two palliative regimens - standard 24 Gray in 3 fractions vs a high-dose (Hi-D) 27 Gray in 3 fractions with dose escalation within the tumor in participants with bulky metastatic cancer.\n\nThe main question",[106,28],"Metastases","2025-12-05",{"date":109,"type":37},"2025-12-18",{"date":111,"type":21},"2026-01-01",{"date":113,"type":21},"2029-08-31",{"name":115,"class":44},"British Columbia Cancer Agency",{"id":117,"slug":118,"hasResults":11,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":122,"eligibilityCriteria":123,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":124,"targetDuration":4,"studyType":22,"phases":126,"briefSummary":127,"conditions":128,"keywords":130,"overallStatus":58,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":45},"100592955","phase-2-lattice-radiation-therapy-for-large-lesions-reggio-emilia-single-arm-phase-ii-trial-100592955","NCT07000162","LAttice Radiation Therapy for Large Lesions: Reggio Emilia Single-arm Phase II Trial","LAttice Radiation Therapy for Large Lesions: Reggio Emilia Single-arm Phase II Trial (LART Trial)","LART","Inclusion Criteria:\n\n* Age ≥18 on day signing informed consent\n* Histologically or cytologically confirmed cancer.\n* Performance status of 0-2 on the ECOG Performance Scale.\n* Advanced or locally advanced disease, not eligible for curative-intent treatment.\n* Life expectancy \\> 6 months.\n* At least one measurable non-brain site of disease with a diameter ≥ 4.5 cm, in any direction\n* Ability to understand and willingness to sign the written informed consent document (or that of legally authorized representative, if applicable).\n\nReproductive Status\n\n* Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU\u002FL or equivalent units of HCG) within 24 hours prior to the start of LRT.\n* Women must not be breastfeeding.\n* WOCBP must agree to follow instructions for method(s) of contraception for the duration of LRT plus 30 days (duration of ovulatory cycle).\n* Men who are sexually active with WOCBP must agree to follow instructions for method(s) of contraception for the duration of LRT plus 90 days (duration of sperm turnover).\n* Investigators shall counsel WOCBP patients and male patients who are sexually active with WOCBP on the importance of pregnancy prevention and the implications of an unexpected pregnancy\n\nExclusion Criteria:\n\n* Additional malignancy that is progressing or requires active treatment. Exceptions include basal and squamous cell carcinoma of the skin or in situ cervical\n* Currently participating in or has participated in a study of an investigational agent or using an investigational device within 2 weeks of the start of LRT.\n* Prior high-dose radiotherapy overlapping with any planned site of protocol radiotherapy, if the dose overlap is \\> 10 Gy or is determined not safe by the treating physician.\n* HIV patients with CD4+ T-cell counts \\\u003C 350 cells\u002FmcL or with a history of AIDS-defining opportunistic infection, within the 12 months prior to registration",{"count":125,"type":21},56,[78],"This study evaluates the activity and toxicity of Lattice Radiation Therapy (LRT) in patients with large, unresectable non-brain neoplastic lesions requiring palliative treatment. Eligible patients will 5 fractions LRT, delivered in every other day, to 20 Gy with a simultaneous boost to a minimum median dose of 50 Gy. No concomitant antineoplastic drugs will be allowed. Patients will be followed at 14, 30, 60, and 90 days after treatment, then every 3 months up to 1 year. Tumor response will be assessed using objective response rate (ORR) per RECIST 1.1, with CT scans at 3, 6, 9, and 12 months. Secondary endpoints include local control, toxicity (CTCAE v.5.0), and patient-reported outcomes (PROMs) to assess their quality of life (EORTC QLQ-C15-PAL and PRO-CTCAE). Exploratory objectives will assess the immunomodulatory effects of LRT through immune cell characterization and quantification of immune-related circulating factors before and after treatment.",[129,28],"Cancer",[131,132,133,134,135],"Lattice radiotherapy","Lattice radiation therapy","Spatially Fractionated Radiation Therapy","Large cancers","Palliative radiotherapy","2025-08-28",{"date":138,"type":37},"2025-08-29",{"date":140,"type":37},"2025-05-26",{"date":142,"type":21},"2028-05-01",{"name":144,"class":145},"Azienda USL Reggio Emilia - IRCCS","OTHER_GOV"]